^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    midazolam hydrochloride

    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    GABA A receptor agonist
    Associations

    News

    Trials
    1d
    Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery (clinicaltrials.gov)
    P=N/A, N=90, Not yet recruiting, Sohag University
    New trial
    |
    midazolam hydrochloride
    9d
    Cannabis Use on Sedation for Oral Surgery Procedures (clinicaltrials.gov)
    P4, N=0, Withdrawn, University of Oklahoma | N=60 --> 0 | Trial completion date: Jun 2025 --> Sep 2025 | Recruiting --> Withdrawn | Trial primary completion date: May 2025 --> Sep 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    midazolam hydrochloride
    9d
    To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, SpringWorks Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Mar 2026
    Enrollment closed • Trial completion date • Trial initiation date
    |
    Ogsiveo (nirogacestat) • midazolam hydrochloride • omeprazole
    12d
    Transversus Abdominis Plan (TAP) Block In Transcatheter Aortic Valve Implantation (TAVI) (clinicaltrials.gov)
    P=N/A, N=50, Completed, Istanbul University - Cerrahpasa | Recruiting --> Completed | Trial completion date: Jun 2025 --> Feb 2026 | Trial primary completion date: Apr 2025 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    midazolam hydrochloride
    14d
    Physiologically-Based Pharmacokinetics of Ribociclib Drug-Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer. (PubMed, Pharmaceuticals (Basel))
    PBPK modeling predicted that ritonavir or erythromycin (strong and moderate CYP3A4 inhibitors) would increase ribociclib steady-state area under the concentration-time curve (AUC) by 1.84-fold or show no meaningful impact, respectively. Steady-state ribociclib AUC was estimated to decrease by 83% and 74% with rifampicin and efavirenz, strong and moderate CYP3A4 inducers, respectively. Ribociclib was estimated to increase CYP3A4 substrate midazolam exposure by 280%. Mild HI or mild/moderate RI did not show an apparent impact on ribociclib PK. Using relevant data and methodology for EBC patients, this analysis informed the approved ribociclib label of no dose adjustment for EBC patients with concomitant use of a moderate CYP3A inhibitor, any degree of HI, or mild/moderate RI, and a reduced 200 mg dose for patients with concomitant use of a strong CYP3A inhibitor or severe RI.
    PK/PD data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Kisqali (ribociclib) • efavirenz • midazolam hydrochloride • rifampicin • ritonavir
    14d
    HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids (clinicaltrials.gov)
    P=N/A, N=112, Recruiting, Chinese University of Hong Kong | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    midazolam hydrochloride
    14d
    A Study of LY4268989 (MORF-057) in Healthy Participants (clinicaltrials.gov)
    P1, N=144, Completed, Eli Lilly and Company | Recruiting --> Completed
    Trial completion
    |
    midazolam hydrochloride
    16d
    Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (clinicaltrials.gov)
    P4, N=96, Completed, Qianfoshan Hospital
    New P4 trial
    |
    midazolam hydrochloride
    23d
    A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007) (clinicaltrials.gov)
    P1, N=28, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole • midazolam hydrochloride
    24d
    DEMISE-MT: Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (clinicaltrials.gov)
    P3, N=56, Recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh | Not yet recruiting --> Recruiting
    Enrollment open
    |
    midazolam hydrochloride
    25d
    Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects (clinicaltrials.gov)
    P1, N=14, Completed, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Completed
    Trial completion
    |
    midazolam hydrochloride
    25d
    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) (clinicaltrials.gov)
    P1/2, N=713, Active, not recruiting, Amgen | Trial primary completion date: Feb 2026 --> May 2026
    Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • midazolam hydrochloride